News
RheumNow Podcast – DESIREABLE Results (5.3.19)
Dr. Jack Cush reviews the latest journal articles and rheumatology news from the past week on RheumNow.com:
Nonadherence is Costly for Patients in Pain
A comparative cohort study of patients with osteoarthritis (OA), gout, diabetic peripheral neuropathy (pDPN), post-herpetic neuralgia (PHN), and fibromyalgia (FM) shows that nonadherence to pain medications is high and leads to greater overall health care resource utilization and costs.
Ideal Outcomes are Seldom Achieved in Gout
Studies from a cohort of gout patients in Mexico shows that long-term goals of a target serum urate (sUA) 6 mg/dL and remission are rare, especially for those with severe gout.
Omega-3 Rich Fish Lowers Gout Flares
Boston researchers have shown that consumption of fish rich in omega‐3 polyunsaturated fatty acids (n‐3 PUFA) leads to a lower risk of recurrent gout flares.
FDA Adds Boxed Warning to Sleep Drugs
The Food and Drug Administration (FDA) added a Boxed Warning to several sleep medications (e.g., eszopiclone, zaleplon, and zolpidem), warning rare but serious injuries may occur as a result of abnormal sleep behaviors (sleepwalking, sleep driving, and engaging in other activities while not
High GPA Hospital Readmission Rates
A national database reveals that patients with granulomatosis with polyangiitis (GPA) have 22.3% risk of hospital readmissions within 30 days of discharge.
From a total of 9749 hospital admissions with GPA, there were 2173 readmissions within 30 days of discharge.
New ACR/AF Guidelines on JIA Polyarthritis and Uveitis
The American College of Rheumatology (ACR) and the Arthritis Foundation (AF) have released two guidelines on management of juvenile idiopathic arthritis (JIA).
Shorter Treatment Succeeds in Septic Arthritis
Two weeks of antibiotic therapy was as effective as 4 weeks for septic arthritis, a prospective single-center study found.
Targeting GM-CSF Works in Rheumatoid Arthritis
Namilumab, a monoclonal antibody that targets the granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand, showed promise as a treatment for rheumatoid arthritis (RA) in a phase II study.
RheumNow Podcast – Take it Back Jack! (4.26.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Naproxen has no Effect on Alzheimer's
A randomized controlled trial shows that chronic low-dose naproxen does not reduce progression of presymptomatic Alzheimer disease (AD).
